SIGMAR1 and epilepsy: Although CBD displays antagonist-like activity toward SIGMAR1 receptor to reduce the negative effects of NMDAR overactivity in epilepsy (Rodríguez-Muñoz et al., 2018), our results showed that chronic CBD administration or coadministration with VPA did not affect the gene expression levels of SIGMAR1.